Skip to search formSkip to main contentSkip to account menu

duloxetine

Known as: N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine, N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide 
A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with… 
National Institutes of Health

Related topics

Related topics

10 relations

Narrower (2)

CymbaltaLY 227942
Duloxetine:MCnc:Pt:Ser/Plas:QnDuloxetine:PrThr:Pt:Urine:OrdDuloxetine:PrThr:Pt:Urine:Ord:Confirmduloxetine 20 MG Delayed Release Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Agomelatine and Duloxetine Synergistically Modulates Apoptotic Pathway by Inhibiting Oxidative Stress Triggered Intracellular Calcium Entry in Neuronal PC12 Cells: Role of TRPM2 and Voltage-Gated…
Calcium ion (Ca2+) is one of the universal second messengers, which acts in a wide range of cellular processes. Results of recent… 
Highly Cited
2013
Highly Cited
2013
Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats
2011
2011
Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial
Antidepressant drugs have often been used as an augmentation strategy for those patients who have demonstrated a suboptimal… 
2008
2008
Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance
Review
2008
Review
2008
Nonsurgical treatment of stress urinary incontinence (SUI): grading of evidence in systematic reviews
Background  The guidance on SUI has not been rigorously assessed using GRADE system. 
Highly Cited
2007
Highly Cited
2007
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
OBJECTIVE To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare… 
Highly Cited
2006
Highly Cited
2006
Duloxetine in the prevention of relapse of major depressive disorder
Background Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission… 
Highly Cited
2006
Highly Cited
2006
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition
Highly Cited
2003
Highly Cited
2003
Mixed Urinary Incontinence Symptoms: Urodynamic Findings, Incontinence Severity, and Treatment Response
Review
2002
Review
2002
Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
Preclinical and clinical studies support the rationale that development of single molecules, which would promote serotonergic and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)